Literature DB >> 2444247

Iris atrophy with hypoperfusion and microneovascularisation.

A M Brooks1, W E Gillies.   

Abstract

A series of 17 patients with stromal atrophy, hypoperfusion, and microneovascularisation of the iris investigated in the Glaucoma Investigation and Research Unit are described, and their iris angiograms were compared with those of normal irides of patients in the same age group seen in general clinics. In all but one of the 17 cases this iris atrophy was associated with glaucoma or ocular hypertension, which appeared to be secondary to the iris changes. The condition was bilateral and presented a typical slit-lamp appearance, with subtle evidence of microneovascularisation. There was neither history nor clinical evidence of previous trauma, heterochromia, or intraocular inflammation. The commonest form of iris atrophy affected the inner third of the iris stroma in a patchy manner, often with sparing above. However, diffuse atrophy occurred in two cases, and there were two cases of 'senile tears' of the iris. Some accompanying atrophy of the pigment epithelium was usual but less prominent. The changes on fluorescein angiography of the iris included the late appearance of dye with a long arteriovenous circulation time, fewer arteries than normal with sectorial hypoperfusion, leakage of dye from the pupil margin and peripupillary neovascularisation, stromal tufts, and sometimes more complex stromal microneovascularisation. An expanded prominent lesser vascular circle was a common feature of the condition. The condition is bilateral and distinct from other forms of iris atrophy. In all cases the iris changes appeared to be secondary to the vascular hypoperfusion and were not consistently associated with evidence of gross vascular disease. All patients had grey (blue) irides, and this may be an aetiological factor. The condition appears common enough to form a significant group of glaucoma patients and to be a separate clinical entity.

Entities:  

Mesh:

Year:  1987        PMID: 2444247      PMCID: PMC1041280          DOI: 10.1136/bjo.71.9.706

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  Essential atrophy of the iris; a histopathologic study.

Authors:  P HEATH
Journal:  Am J Ophthalmol       Date:  1954-02       Impact factor: 5.258

2.  Fluorescein angiography of the iris in anterior segment pigment dispersal syndrome.

Authors:  W E Gillies; C Tangas
Journal:  Br J Ophthalmol       Date:  1986-04       Impact factor: 4.638

3.  Progressive changes in the angle in congenital aniridia, with development of glaucoma.

Authors:  W M Grant; D S Walton
Journal:  Am J Ophthalmol       Date:  1974-11       Impact factor: 5.258

4.  Vascular changes in pseudoexfoliation of the lens capsule and capsular glaucoma. A fluorescein angiographic and electron microscopic study.

Authors:  A Vannas
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1972

5.  Classification of corneal endothelial disorders based on neural crest origin.

Authors:  C F Bahn; H F Falls; G A Varley; R F Meyer; H F Edelhauser; W M Bourne
Journal:  Ophthalmology       Date:  1984-06       Impact factor: 12.079

6.  The corneal endothelium and the spectrum of essential iris atrophy.

Authors:  D G Campbell; M B Shields; T R Smith
Journal:  Am J Ophthalmol       Date:  1978-09       Impact factor: 5.258

7.  Iridoschisis.

Authors:  P V Mills
Journal:  Br J Ophthalmol       Date:  1967-03       Impact factor: 4.638

8.  Fluorescein iris angiography. I. Normal pattern.

Authors:  S S Hayreh; W E Scott
Journal:  Arch Ophthalmol       Date:  1978-08

9.  Fluorescein angiography and fluorophotometry of the iris in pseudoexfoliation of the lens capsule.

Authors:  A M Brooks; W E Gillies
Journal:  Br J Ophthalmol       Date:  1983-04       Impact factor: 4.638

10.  Anatomical classification of the developmental glaucomas.

Authors:  H D Hoskins; R N Shaffer; J Hetherington
Journal:  Arch Ophthalmol       Date:  1984-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.